The notices it replaced
- Reissues: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 2 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 3 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-16-303.
Who won it before
559 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $176,882,049 in first-year total cost, median $224,999.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-M (11)]45
- Special Emphasis Panel[ZRG1 SBIB-T (10)]42
- Special Emphasis Panel[ZRG1 OTC-T (10)]36
- Special Emphasis Panel[ZRG1 RPHB-C (10)]24
- Special Emphasis Panel[ZRG1 ETTN-G (12)]23
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC6
- CORTICOMETRICS, LLC5
- MEDOSOME BIOTEC, LLC5
- MICROBIOTIX, INC5
- BARRON ASSOCIATES, INC.4
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Peripheral FAAH as a target for novel analgesics2R42DA033683-02A1 · under PA-14-072 | PIOMELLI, DANIELE | ANTEANA THERAPEUTICS, INC., CA | $1,100,244 | ZRG1 |
| 2017 | Validation of Novel Therapeutic Approach for Cryptococcal Meningitis2R42AI120304-02 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $1,000,000 | ZRG1 |
| 2017 | Design and Development of Immunotolerant S. aureus Biotherapies2R42AI118133-02 | BAILEY-KELLOGG, CHRISGRISWOLD, KARL E | LYTICON, LLC, NH | $868,526 | ZRG1 |
| 2017 | Development of user-friendly fluorescence based assays for marine toxins2R42ES023724-02A1 | MCCALL, JENNIFER RETTEW | SEATOX RESEARCH, INC., NC | $854,503 | ZRG1 |
| 2017 | Lactoferrin Modulation of Granuloma Pathology2R42AI117990-02 | ACTOR, JEFFREY KKRUZEL, MARIAN L | PHARMAREVIEW CORPORATION, TX | $815,321 | ZRG1 |
| 2017 | Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery2R42CA192504-02 | SHEKHAR, RAJ | IGI TECHNOLOGIES, INC., MD | $774,136 | ZRG1 |
| 2017 | AutoRegister: A system for enhancing the accuracy of tumor change detection2R42CA183150-02 | VAN DER KOUWE, ANDRE JAN WILLEMWIGHTON, PAUL | CORTICOMETRICS, LLC, MA | $750,000 | ZRG1 |
| 2017 | Development of PAR4 Pepducins as a Novel Antithrombotic Treatment1R41HL134517-01A1 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $366,484 | ZRG1 |
| 2017 | Anti-CCL25 mAb to treat castration resistant prostate cancer1R41CA214080-01 | SINGH, SHAILESH | JYANT, INC., GA | $350,000 | ZRG1 |
| 2017 | Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy1R41CA213463-01 | SZABO, CSABA | CBS THERAPEUTICS, INC., TX | $300,000 | ZRG1 |
| 2017 | DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS1R41EY026849-01A1 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $299,999 | ZRG1 |
| 2017 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis1R41AI122666-01A1 | ADHIKARI, RAJAN PHAKAMI, RAMIN M.NELSON, DANIEL C. | INTEGRATED BIOTHERAPEUTICS, INC., MD | $294,932 | ZRG1 |
| 2017 | Large Scale Preparation of Natural Glycans1R41GM122139-01 | SONG, XUEZHENG | NATGLYCAN, LLC, GA | $285,524 | ZRG1 |
| 2017 | Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer1R41CA213715-01 | LEOPOLD, JUDITH SWHITEHEAD, CHRISTOPHER EMIL | MEKANISTIC THERAPEUTICS, LLC, MI | $275,000 | ZRG1 |
| 2017 | Online Practitioner Training in Behavioral Intervention in Autism: Skill Training Using an Interactive Simulated Child1R41MH116534-01A1 | SERNA, RICHARD W | PRAXIS, INC., MA | $250,387 | ZRG1 |
| 2017 | A novel anti-gonorrhea immunotherapeutic1R41AI129106-01 | RAM, SANJAYWYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $242,093 | ZRG1 |
| 2017 | Novel HDAC Inhibitors for Treatment of Hemoglobinopathies1R41HL136068-01 | PERRINE, SUSAN PARKWILLIAMS, ROBERT MICHAEL | CETYA THERAPEUTICS, INC., CO | $241,742 | ZRG1 |
| 2017 | Developing a new therapeutic agent for retinal ciliopathies1R41EY027667-01 | KATSANIS, NICHOLAS | RESCINDO THERAPEUTICS, INC., NC | $238,837 | ZRG1 |
| 2017 | Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases1R41EY027219-01 | COUSINS, SCOTT WILLIAM | EYEDESIS BIOSCIENCES, LLC, NC | $225,030 | ZRG1 |
| 2017 | Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients.1R41GM119871-01A1 | DILLER, KENNETH R. | MERCURY BIOMED, LLC, OH | $225,000 | ZRG1 |
| 2017 | An integrative multi-phenotype pipeline for drug evaluation, pharmacogenomics, and attribute prediction1R41TR001908-01 | JAEGER, PHILIPP | PHENVOGEN, LLC, CA | $224,991 | ZRG1 |
| 2017 | Soluble E-NTPDase for sepsis1R41GM120838-01A1 | HASKO, GEORGE | PURINE PHARMACEUTICALS, INC., NJ | $224,871 | ZRG1 |
| 2017 | Bioimpedance-based Intracranial Mapping for Monitoring Evolving TBI1R41NS100313-01 | HALTER, RYAN JOSEPH | RYTEK MEDICAL, INC., NH | $224,609 | ZRG1 |
| 2017 | Targeting Synaptotagmin-2 to Prevent Airway Mucus Obstruction1R41HL136057-01 | DICKEY, BURTON FVARADHACHARY, ATUL | EXOTECT, LLC, TX | $224,576 | ZRG1 |
| 2017 | Tools for site-specific antibody immobilization for immunoassays1R41EB023750-01 | TSOURKAS, ANDREW | ALPHATHERA, INC., PA | $224,556 | ZRG1 |
| 2017 | Microparticulate mucosal vaccine for triple-negative breast cancer1R41CA206652-01A1 | CHIRIVA-INTERNATI, MAURIZIOMIRANDOLA, LEONARDO | KIROMIC, INC., TX | $224,522 | ZRG1 |
| 2017 | Automated Electrophysiology Assessment of Drug-induced Cardiotoxicity Based on Parallel, Noninvasive Nanoelectrode Array1R41EB022439-01A1 | JIANG, XIN | CYION TECHNOLOGIES, LLC, CA | $223,028 | ZRG1 |
| 2017 | Application of PPODA-QT for embolization of aneurysms1R41NS097069-01A1 | BECKER, TIM | ANEUVAS TECHNOLOGIES, INC., AZ | $220,109 | ZRG1 |
| 2017 | AML-MutationCounter, a tool to detect residual and recurrent leukemia1R41CA213690-01 | KAUFMANN, WILLIAM K. | ASYSTBIO LABORATORIES, LLC, NC | $220,087 | ZRG1 |
| 2017 | Therapeutic Mabs for Chronic Kidney Disease1R41DK112426-01 | LUKACS, NICHOLAS W | OPSIDIO, LLC, PA | $217,446 | ZRG1 |
| 2017 | A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease1R41DK109737-01A1 | BIDWELL, GENE LEFLORE | LEFLORE TECHNOLOGIES, LLC, MS | $216,429 | ZRG1 |
| 2017 | Novel sanitizer against viral infections with long-lasting effect1R41AI124738-01A1 | HSU, STEPHEN | CAMELLIX, LLC, GA | $192,601 | ZRG1 |
| 2017 | The Patient Centered Postpartum Contraception ToolKit (PC2)1R41HD090825-01 | GILLIAM, MELISSASPARROW, ASHLYN | RESILIENT GAMES STUDIO, LLC, IL | $149,916 | ZRG1 |
| 2017 | eHealth Mobile Technology Connecting Young Adults to Routine Engagement (eMCARE), a theoretically and empirically driven mobile intervention to engage young adults in healthcare.1R41HD090813-01 | SHAABAN, SAMI | NURELM E-BUSINESS SOFTWARE, PA | $149,439 | ZRG1 |
| 2017 | Designing and Evaluating Outcome Assessment Software for Youth with Developmental Disabilities: The Pediatric Evaluation of Disability Inventory- Patient Reported Outcome (PEDI-PRO)1R41HD090772-01 | DAVIES, DANIEL KKRAMER, JESSICA MARVELLE | ABLELINK TECHNOLOGIES, INC., CO | $132,454 | ZRG1 |
| 2016 | Therapeutics for inflammatory bowel disease from the microbiome2R42DK103361-02 | MAZMANIAN, SARKIS K | SYMBIOTIX BIOTHERAPIES, INC., MA | $1,973,386 | ZRG1 |
| 2016 | The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients1UT2HL131226-01 · under PA-14-072 | RODRIGUEZ-BORLADO, LUIS | CAPRICOR, INC., CA | $1,683,381 | ZRG1 |
| 2016 | New generation of catheters for treatment of atrial fibrillation2R42HL120511-02 · under PA-14-072 | SARVAZYAN, NARINE | NOCTURNAL PRODUCT DEVELOPMENT, LLC, NC | $1,173,082 | ZRG1 |
| 2016 | Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms2R42NS074576-03 · under PA-14-072 | KALLMES, DAVID FKEALEY, COLIN PATRICK | NEUROSIGMA, INC., CA | $1,072,694 | ZRG1 |
| 2016 | A Phase 2a clinical trial of ALK-001 in geographic atrophy2R44EY021988-02A1 · under PA-14-072 | SAAD, LEONIDEWASHINGTON, ILYAS | ALKEUS PHARMACEUTICALS, INC., MA | $1,054,287 | ZRG1 |
| 2016 | Developing Therapeutics That Target RAD51 To Treat Leukemia and Lymphoma2R42CA183197-02A1 | MILLS, KEVIN D | CYTEIR THERAPEUTICS, INC., MA | $1,038,983 | ZRG1 |
| 2016 | Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS2R42GM112516-02 | SMITHGALL, THOMAS E. | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,001,024 | ADDT |
| 2016 | Clonotyping Technology for Prediction of Antibiotic Resistance2R42AI116114-02 · under PA-14-072 | KAWASAKI, GLENNOSTER, JEFFREYSOKURENKO, EVGENI VENIAMINOVIC | IDGENOMICS, INC., WA | $999,967 | ZRG1 |
| 2016 | Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens2R42AI108029-03 | GEISBERG, MARK | SILVER LAKE RESEARCH CORPORATION, CA | $994,558 | ZRG1 |
| 2016 | Humanized Monoclonal Antibody to Treat Acinetobacter Infections2R42AI106375-03 | ISLAM, KHALID | BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC, MD | $982,415 | ZRG1 |
| 2016 | SMALL MOLECULE ANTAGONISTS OF PF4 FOR THE TREATMENT AND PREVENTION OF HIT2R42HL123126-02 · under PA-14-072 | SACHAIS, BRUCE S | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $980,000 | ZRG1 |
| 2016 | Delivery of peptides for inducing voiding associated with neurological retention2R42NS092178-02 | MARSON, LESLEY | DIGNIFY THERAPEUTICS, LLC, NC | $953,265 | ZRG1 |
| 2016 | Development of VLP vaccine for RSV2R42AI109926-02 | BLANCO, JORGE C | SIGMOVIR BIOSYSTEMS, INC., MD | $933,962 | ZRG1 |
| 2016 | Pre-Clinical Safety and Efficacy of TRB-N0224 for the Treatment of Periodontal Disease2R42DE024946-02 | GOLUB, LORNE MGU, YING | TRAVERSE BIOSCIENCES, INC., NY | $888,810 | ZRG1 |
| 2016 | AcetaSTAT Rapid Assay for Acetaminophen Liver Injury2R42DK079387-06A1 | JAMES, LAURA PHILLIPS | ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC, AR | $875,076 | ZRG1 |
| 2016 | Wireless sensor and telemedicine to screen for sleep apnea in elderly adults2R42MD008845-02 | ARNEDT, J. TODD | ZANSORS, LLC, VA | $802,553 | ZRG1 |
| 2016 | Optimized lactoferrin for treatment of intracerebral hemorrhage2R42NS090650-02 | ARONOWSKI, JAROSLAWKRUZEL, MARIAN L | PHARMAREVIEW CORPORATION, TX | $776,623 | ZRG1 |
| 2016 | Mutation Enriched Targeted Re-Sequencing2R42CA180389-02A1 · under PA-14-072 | MAKRIGIORGOS, G. MIKEWU, GRANT | TRANSGENOMIC, INC., NE | $773,511 | ZRG1 |
| 2016 | Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD2R42AI104034-03A1 | MAHER, PAMELA ANNE | VIROGENICS, INC., CA | $771,449 | ZRG1 |
| 2016 | Enhancing Care of the Aged and Dying in Prisons2R42AG049570-02 | LOEB, SUSAN JAYNEPENROD, JANICE L | KLEIN BUENDEL, INC., CO | $766,067 | ZRG1 |
| 2016 | A user-friendly scalable microfluidic platform for enhanced neuron-cell culture2R42MH097377-03A1 | TAYLOR, ANNE MARION | XONA MICROFLUIDICS, LLC, NC | $763,929 | ZRG1 |
| 2016 | The CellRaft AIR System: Workflow Automation for Stem Cell Isolation and Recovery2R42GM106421-02 · under PA-14-072 | ALLBRITTON, NANCY L. | CELL MICROSYSTEMS, INC., NC | $748,655 | ZRG1 |
| 2016 | Simultaneous, Proportional and Independent sEMG-Based Hand-Wrist Prosthesis Control2R42HD076519-02 | CLANCY, EDWARD A | LIBERATING TECHNOLOGIES, INC., MA | $742,455 | ZRG1 |
| 2016 | New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry2R42AI112302-02 | PITNER, JAMES BRUCE | NIRVANA SCIENCES, INC., NC | $738,015 | ZRG1 |
| 2016 | Memory Care Partner2R42AG044147-02A1 · under PA-14-072 | ANDERSEN, TROYFOSTER, NORMAN LOUIS | PROACTIVE MEMORY SERVICES, INC., UT | $734,115 | ZRG1 |
| 2016 | Development and validation of therapy for mucopolysaccharidosis III2R42NS089061-02 | EKINS, SEAN | PHOENIX NEST, INC., NY | $717,207 | ZRG1 |
| 2016 | Development of small near-infrared laser system capable of improving immune responses to vaccines (laser-based adjuvant)2R42AI114012-02 · under PA-14-072 | BEAN, DAVID | VERALASE, LLC, MA | $696,264 | ZRG1 |
| 2016 | Automated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record2R42CA180190-02A1 | MEYSTRE, STEPHANE | CLINACUITY,INC., SC | $684,880 | ZRG1 |
| 2016 | Medical Sensor Applications of Tunnel Magnetoresistance (TMR)2R42DC012725-02A1 | KNUESEL, ROBERT J | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $624,323 | ZRG1 |
| 2016 | Single Cell Analysis via Nanoscale Tip-Enhanced Laser Ablation Mass Spectrometry2R42GM106454-02 · under PA-14-072 | MURRAY, KERMIT KING | ANASYS INSTRUMENTS CORPORATION, CA | $597,820 | ZRG1 |
| 2016 | Newborn Infant Vision Test2R42EY022545-02A1 | KOPIDLANSKY, EDWARD G | PRECISION VISION, INC., IL | $587,619 | ZRG1 |
| 2016 | Identifying activators of interferon regulatory factors for neuroprotection.2R42NS095538-02 | STENZEL-POORE, MARY P | NEURALEXO, LLC, OR | $506,682 | ZRG1 |
| 2016 | Macromolecule Crystallization Screening Results Analysis2R42GM116283-02 | PUSEY, MARC LEE | IXPRESSGENES, INC., AL | $489,775 | ZRG1 |
| 2016 | In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma2R42CA168123-02A1 | CHENEY, DARWIN LEROYGHANDEHARI, HAMID | THERATARGET, UT | $400,462 | ZRG1 |
| 2016 | A Novel Biologic for the Treatment of Hypogonadism1R41AG053124-01 | ATWOOD, CRAIG S | JANGOBIO, LLC, WI | $364,157 | ZRG1 |
| 2016 | 4-(Aminomethyl) benzamides as novel anti-Ebola agents1R41AI126971-01 | RONG, LIJUN | CHICAGO BIOSOLUTIONS, INC., IL | $363,601 | ZRG1 |
| 2016 | High-potency nitro antimicrobials for topical treatment of trichomoniasis1R41AI118089-01A1 · under PA-14-072 | ECKMANN, LARSPEYTON, DAVID H | DESIGNMEDIX, INC., OR | $353,902 | ZRG1 |
| 2016 | A microfluidic quality-control assay for stem-cell derived therapies1R41TR001203-01A1 · under PA-14-072 | NEUMANN, THOMAS | NORTIS, INC., WA | $325,000 | ZRG1 |
| 2016 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer1R41CA203456-01A1 | MARATHI, UPENDRAOVERWIJK, WILLEM WWOODSIDE, DARREN G | 7 HILLS PHARMA, LLC, TX | $313,705 | ZRG1 |
| 2016 | T3SS needle protein inhibitors for the treatment of P. aeruginosa infection1R41AI122433-01 · under PA-14-072 | MECSAS, JOAN C | MICROBIOTIX, INC, MA | $302,983 | ZRG1 |
| 2016 | Combinatorial Inactivation of ERBB Receptors in Breast Cancer using Therapeutic Stapled Peptides1R41CA203353-01 · under PA-14-072 | SCHROEDER, JOYCE A | ARIZONA CANCER THERAPEUTICS, LLC, AZ | $300,000 | ZRG1 |
| 2016 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer1R41CA200161-01A1 · under PA-14-072 | SONENSHEIN, GAIL E. | ADECTO PHARMACEUTICALS, INC., MA | $300,000 | ZRG1 |
| 2016 | Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors1R41CA192419-01A1 | CHEN, THOMAS C.HOFMAN, FLORENCE M | NEONC TECHNOLOGIES, INC., CA | $300,000 | ZRG1 |
| 2016 | Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection1R41AI118120-01A1 | KAZMIERCZAK, BARBARA I | L2 DIAGNOSTICS, LLC, CT | $300,000 | ZRG1 |
| 2016 | Aminoglycosides with reduced ototoxicity1R41AI126874-01 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $300,000 | ZRG1 |
| 2016 | Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings1R41AI124932-01A1 | STEVENSON, MARIO | DISCIDIUM BIOSCIENCES, LLC, FL | $300,000 | ZRG1 |
| 2016 | Inhibitors of the viral nucleoprotein-polymerase co-factor interaction for human RSV and MPV therapy1R41AI127009-01 | MOIR, DONALD T | MICROBIOTIX, INC, MA | $300,000 | ZRG1 |
| 2016 | Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways1R41AI124851-01A1 | JONES, CHARLES HOUSTON | ABCOMBI BIOSCIENCES, INC., NY | $300,000 | ZRG1 |
| 2016 | Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases1R41AI127055-01 | HENKEL, GREGORY WILLIAMYANIK, AHMET ALI | ARISAN THERAPEUTICS, INC., CA | $300,000 | ZRG1 |
| 2016 | Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis1R41CA213718-01 | JUNKER, WADE MKAUR, SUKHWINDER | SANGUINE DIAGNOSTICS AND THERAPEUTICS, NE | $300,000 | ZRG1 |
| 2016 | Highly specific ATR inhibitors for the targeted treatment of a broad spectrum of cancers1R41CA203436-01A1 | BROWN, ERIC JGILAD, OREN | ATRIN PHARMACEUTICALS, PA | $299,998 | ZRG1 |
| 2016 | Optimization of a novel cancer immunotherapeutic antibody for human use1R41CA206688-01A1 | WU, JENNIFER D | CANCURE, LLC, WA | $299,994 | ZRG1 |
| 2016 | A universal vaccine for the prevention of meningococcal meningitis in Africa1R41AI124759-01A1 | MOE, GREGORY ROBERT | OMVAX, INC., CA | $299,970 | ZRG1 |
| 2016 | A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization1R41CA213909-01 | HUNTER, WILLIAM COULIS JASON | PET/X, LLC, WA | $299,970 | ZRG1 |
| 2016 | Simvastatin nanomedicine in ARDS and sepsis1R41GM121153-01 | ROBERTS, SHAWN KENNY | EUNOIA BIO TECH, LLC, PA | $299,940 | ZRG1 |
| 2016 | Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors1R41CA206859-01A1 | DURDEN, DONALD | SIGNALRX PHARMACEUTICALS, INC., GA | $299,738 | ZRG1 |
| 2016 | Precision, pulmonary disease evaluation and lung cancer detection using quantitative low-dose CT1R41CA206646-01 | SIEREN, JESSICA C | VIDA DIAGNOSTICS, INC., IA | $299,713 | ZRG1 |
| 2016 | Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma1R41CA195908-01A1 · under PA-14-072 | WAJAPEYEE, NARENDRA | L2 DIAGNOSTICS, LLC, CT | $298,959 | ZRG1 |
| 2016 | B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer1R41CA213544-01 | DAHL, JEREMYUNGER, EVAN CHARLES | NUVOX PHARMA, LLC, AZ | $298,820 | ZRG1 |
| 2016 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development1R41CA203090-01 · under PA-14-072 | UNGER, EVAN CHARLESWILLMANN, JUERGEN KARL | NUVOX PHARMA, LLC, AZ | $297,786 | ZRG1 |
| 2016 | Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance1R41DK109753-01 | WILSON, GLENN | EXSCIEN CORPORATION, AL | $296,128 | ZRG1 |
| 2016 | A small molecule integrin activator to enhance cord blood transplant1R41HL129612-01A1 | MARATHI, UPENDRAVANDERSLICE, PETER | 7 HILLS PHARMA, LLC, TX | $295,931 | ZRG1 |
| 2016 | Novel antibacterial agents derived from natural products1R41AI118104-01A1 · under PA-14-072 | PRIESTLEY, NIGEL D | PROMILIAD BIOPHARMA, INC., MT | $295,729 | ZRG1 |
| 2016 | Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin1R41AI122441-01A1 | SMITH, JAMES LEIF | SANO CHEMICALS, INC, TX | $295,381 | ZRG1 |
| 2016 | Monospecific monoclonal antibodies against human protein complexes on an interactome-wide scale.1R41CA210822-01 | LACAVA, JOHN | CDI LABORATORIES, INC., PR | $294,320 | ZRG1 |
| 2016 | Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria1R41AI115915-01A1 · under PA-14-072 | JUNG, DAVID | AGILE SCIENCES, INC., NC | $294,309 | ZRG1 |
| 2016 | Proteolytic Imaging of Remodeling Myocardium1R42HL131280-01A1 | SPINALE, FRANCIS G | MICRO VIDE, LLC, SC | $294,131 | ZRG1 |
| 2016 | Development of Optimized AAV Serotype Vectors for Human Gene Therapy1R41AI122735-01 · under PA-14-072 | SRIVASTAVA, ARUN | MEDOSOME BIOTEC, LLC, FL | $294,094 | ZRG1 |
| 2016 | A Method to Increase Buprenorphine Treatment Capacity and Effectiveness1R42DA041941-01A1 | LISS, ROSALYNSHI, JULIA | CBT4CBT, LLC, FL | $293,694 | ZRG1 |
| 2016 | Development of peptide inhibitors for neuroinflammation and neurodegeneration1R41AG053117-01 | SRINIVASAN, MYTHILY | PROVAIDYA, INC., IN | $284,145 | ZRG1 |
| 2016 | A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development1R41CA195777-01A1 · under PA-14-072 | LIU, JASMINE JINGYUAN | QRKANSWER, IN | $279,838 | ZRG1 |
| 2016 | Novel SCD1 inhibitors for treatment of cancer1R41CA195946-01A1 · under PA-14-072 | COPLAND, JOHN A.HAZLEHURST, LORI | MODULATION THERAPEUTICS, INC., WV | $279,000 | ZRG1 |
| 2016 | HELical Biodegradable Photochemical(HELP)Stents for AVF Maturation1R41DK111332-01 | ROY-CHAUDHURY, PRABIR | INOVASC, LLC, OH | $275,529 | ZRG1 |
| 2016 | An epitope-focused nanoparticle vaccine for MRSA and biodefense1R41AI122594-01 · under PA-14-072 | OSCHERWITZ, JONWHITACRE, DAVID C | VLP BIOTECH, INC., CA | $273,748 | ZRG1 |
| 2016 | Digital Gene Expression Analysis by 3’ End Sequencing1R41HG008921-01 · under PA-14-072 | TIAN, BINTOLOUE, MASOUD | BIOO SCIENTIFIC CORPORATION, TX | $270,000 | ZRG1 |
| 2016 | Drug Activation of HSF1 for Prevention of Noise-Induced Hearing Loss1R41DC015411-01A1 | KOHRMAN, DAVID CSIPPOLA-THIELE, MARIA SIRPA | CHAPERONE THERAPEUTICS, INC., NC | $269,999 | ZRG1 |
| 2016 | Product Development of Intensity Modulation for Bolus Electron Conformal Therapy1R41CA199838-01A1 | ERHART, KEVIN JAMES | DECIMAL, INC., FL | $261,141 | ZRG1 |
| 2016 | A chimeric protein for the selective expansion of regulatory T cells1R41AI125039-01 | PRABHAKAR, BELLUR S | SAHANE BIOTECH, INC., IL | $260,665 | ZRG1 |
| 2016 | Automated Object Contouring Methods & Software for Thoracic Radiotherapy Planning1R41CA199735-01A1 | UDUPA, JAYARAM K | QUANTITATIVE RADIOLOGY SOLUTIONS, LLC, PA | $254,097 | ZRG1 |
| 2016 | Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis1R41AI122780-01A1 | DAMSKER, JESSE | REVERAGEN BIOPHARMA, INC., MD | $253,802 | ZRG1 |
| 2016 | A method for accurate and sensitive detection of HIV drug-resistant minority variants1R41AI122855-01A1 | WANG, GARY P. | MEDOSOME BIOTEC, LLC, FL | $253,244 | ZRG1 |
| 2016 | Targeted and Non-targeted Microbubbles for Pediatric Applications1R41HD089823-01 | KUTTY, SHELBYUNGER, EVAN CHARLES | NUVOX PHARMA, LLC, AZ | $243,164 | ZRG1 |
| 2016 | 4-Aminopiperidines as novel anti-influenza agents1R41AI127031-01 | RONG, LIJUN | CHICAGO BIOSOLUTIONS, INC., IL | $242,913 | ZRG1 |
| 2016 | Generation of antibodies to monitor Notch O-fucosylation in vivo1R41GM119879-01A1 | ORLANDO, RON | GLYCOSCIENTIFIC, LLC, GA | $242,306 | ZRG1 |
| 2016 | A brief iPad-based screening measure for HIV-associated neurocognitive disorders2R42MH099964-02A1 | MARCOTTE, THOMAS DSEVERSON, JOAN M | DIGITAL ARTEFACTS, LLC, IA | $240,880 | ZRG1 |
| 2016 | Nanoparticle Delivery System for Ewing Sarcoma Treatment1R41CA203457-01A1 | NAGY, JON OWENTRICHE, TIMOTHY J. | NANOVALENT PHARMACEUTICALS, INC., MT | $240,750 | ZRG1 |
| 2016 | Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions1R41GM116530-01A1 · under PA-14-072 | NAGY, JON OWENWONG, JOYCE Y | NANOVALENT PHARMACEUTICALS, INC., MT | $238,728 | ZRG1 |
| 2016 | Molecular Imaging of Early Stage of Liver Fibrosis by Novel Protein Agents1R41AA025863-01 | YANG, JENNY J. | INLIGHTA BIOSCIENCES, LLC, GA | $238,587 | ZRG1 |
| 2016 | Streamlining HTS Assay Development through Direct Selection of Structure-Switching Aptamers1R41GM121123-01 | HEEMSTRA, JENNIFER MARGARETLOWERY, ROBERT G | BELLBROOK LABS, LLC, WI | $234,936 | ZRG1 |
| 2016 | Biological super-resolution imaging using high-index microspheres for cancer research application1R41GM117844-01 · under PA-14-072 | CARABE-FERNANDEZ, ALEJANDRODARAFSHEH, ARASHLEE, DAEYEON | SPHEREVIS, LLC, PA | $233,419 | ZRG1 |
| 2016 | Optimizing Vaccines by Targeting Dendritic Cells with IFNa and IFNb Inducing Adjuvants1R41AI118522-01A1 · under PA-14-072 | DANLEY, DAVID LAWRENCE | PARABON NANOLABS, INC., VA | $230,000 | VACC |
| 2016 | Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease1R41AI122403-01 · under PA-14-072 | AMAN, M JAVADLAI, JONATHAN R. | INTEGRATED BIOTHERAPEUTICS, INC., MD | $229,991 | ZRG1 |
| 2016 | Blockade of histamine-releasing factor as a new prophylactic and therapeutic strategy for food allergy1R41AI124734-01 | KAWAKAMI, TOSHIAKIMARUYAMA, TOSHIAKI | ABWIZ BIO, INC., CA | $229,600 | ZRG1 |
| 2016 | STAT Inhibitors for Asthma Therapy1R41AI125007-01A1 | CORRY, DAVID B | ATRAPOS THERAPEUTICS, LLC, TX | $227,537 | ZRG1 |
| 2016 | High-speed Intraoperative Assessment of Breast Tumor Margin using MarginPAT1R41CA200006-01A1 | CHENG, JI-XIN | VIBRONIX, INC., IN | $225,943 | ZRG1 |
| 2016 | A NEW HOLOGRAPHIC 3D CAMERA FOR FUNDUS IMAGING1R41EY026826-01A1 | BROOKER, GARY | CELLOPTIC, INC., MD | $225,635 | ZRG1 |
| 2016 | A High Resolution Radiation Therapy Dosimetry system1R41CA202980-01A1 | LI, HAROLD HUI | DOSEIMAGING, LLC, MO | $225,001 | ZRG1 |
| 2016 | PEGYLATED PEPTIDES LIGANDS TARGETING RADIATION-INDUCIBLE RECEPTORS ON CANCER1R41CA196002-01A1 · under PA-14-072 | DEVANATHAN, SRIRAM | MEDICAL GUIDANCE SYSTEMS, LLC, MO | $225,000 | ZRG1 |
| 2016 | Aerosol Sampling and Microfluidic Analysis of Reactive Oxygen Species1R42ES026532-01 · under PA-14-072 | ZYUZIN, ALEXEI | ILLIONIX, LLC, WA | $225,000 | ZRG1 |
| 2016 | Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy1R41GM117974-01 · under PA-14-072 | POWELL, RICHARD DENIS | NANOPROBES, INC., NY | $225,000 | ZRG1 |
| 2016 | Developing a novel adjuvant system for therapeutic vaccines against lung cancer1R41CA199956-01A1 | SHIRWAN, HAVAL | FASCURE THERAPEUTICS, LLC, KY | $225,000 | ZRG1 |
| 2016 | Development of a kit for characterization of cellular energetics in single cells in cell and tissue cultures based on the measurement of the absolute magnitude of the mitochondrial membrane potential1R41DA043369-01 | GERENCSER, AKOS A | IMAGE ANALYST SOFTWARE, CA | $225,000 | ZRG1 |
| 2016 | Jamboxx: Interactive Respiratory Therapy through Music and Gaming1R42HL132735-01 | DICESARE, MICHAEL | MY MUSIC MACHINES, INC., NY | $225,000 | ZRG1 |
| 2016 | Small, high-affinity ligands for array tomography1R41MH110321-01 | HACKEL, BENJAMINLENZI, DAVID PETER | ARATOME, LLC, CA | $225,000 | ZRG1 |
| 2016 | PlusOne: Prototyping and Validation of a Wireless In-Home Breathing Monitor for Prevention of Overdose Deaths1R41DA041960-01 | MAAS, DUSTINPATWARI, NEALPORUCZNIK, CHRISTINA | XANDEM TECHNOLOGY, LLC, UT | $225,000 | ZRG1 |
| 2016 | An Agent-Based Modeling Platform for Environmental Biotechnology1R41ES026541-01A1 | MOFRAD, MOHAMMAD RKSHIRAZI, FATEMEH | MICROVI BIOTECH, INC., CA | $225,000 | ZRG1 |
| 2016 | A New Prostate Cancer Treatment to Improve Outcomes and Reduce Side-effects1R41CA210737-01 | FLYNN, RYAN THOMAS | PXALPHA, LLC, IA | $225,000 | ZRG1 |
| 2016 | An Automated Patient Chart Error Detection System for Radiation Therapy1R41CA195819-01A1 | XIA, JUNYI | INFONDRIAN, LLC, IA | $225,000 | ZRG1 |
| 2016 | Developing novel RPPA for the detection of metastatic prostate cancer1R41CA210772-01 | TAO, W. ANDY | TYMORA ANALYTICAL OPERATIONS, LLC, IN | $225,000 | ZRG1 |
| 2016 | Validation of a salivary miRNA diagnostic test for autism spectrum disorder1R41MH111347-01 | MIDDLETON, FRANK A. | QUADRANT BIOSCIENCES, INC., NY | $225,000 | ZRG1 |
| 2016 | A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes1R41DK106779-01A1 | MANNING, HENRY CHARLES | CUMBERLAND PHARMACEUTICALS, INC., TN | $224,999 | ZRG1 |
| 2016 | Smart Residential Carpet for Promoting Aging in Place1R41AG053108-01 | NAJAFI, BIJAN | BIOSENSICS, LLC, MA | $224,999 | ZRG1 |
| 2016 | A novel protein engineering tool for rapid manufacturing of designer nucleosomes1R41CA214076-01 | SUN, ZU-WEN | EPICYPHER, INC., NC | $224,999 | ZRG1 |
| 2016 | Novel small-molecule targeted therapy for prostate cancer1R41CA206725-01A1 | WU, DAQING | METCURE THERAPEUTICS, LLC, GA | $224,999 | ZRG1 |
| 2016 | A mobile app to reduce treatment-related financial burden for cancer patients1R42CA210699-01 | ZAFAR, SYED YOUSUF | VIVOR, LLC, NY | $224,997 | ZRG1 |
| 2016 | Stabilization of Influenza Vaccine by Silica-Coating1R41AI126940-01 | LAIDLER, JAMES RSTEDMAN, KENNETH MARK | STONESTABLE, INC., OR | $224,993 | ZRG1 |
| 2016 | Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis1R41CA196011-01A1 · under PA-14-072 | ORTON, DARREN | STEMSYNERGY THERAPEUTICS, INC., FL | $224,991 | ZRG1 |
| 2016 | Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates1R41AR070088-01 | FRIIS, ELIZABETH A | EVOKE MEDICAL, LLC, KS | $224,991 | ZRG1 |
| 2016 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases1R42HD089804-01 | STACPOOLE, PETER WALLACE | MEDOSOME BIOTEC, LLC, FL | $224,978 | ZRG1 |
| 2016 | Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus1R41AI122566-01 · under PA-14-072 | PROBST, PETERSTEVENS, ANNE MARGUERITE | KINETA, INC., WA | $224,977 | ZRG1 |
| 2016 | Expanding teleconsent capabilities to improve clinical research recruitment1R41LM012547-01A1 | WELCH, BRANDON M | DOXY.ME, LLC, SC | $224,972 | ZRG1 |
| 2016 | Directed Chemotherapy Delivery for Leptomeningeal Metastases1R41CA206744-01 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $224,970 | ZRG1 |
| 2016 | Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse Medications1R41AA025298-01 | TOLL, LAWRENCE R | ASSUAGE PHARMACEUTICALS, INC., FL | $224,956 | ZRG1 |
| 2016 | Optimization of Pre- and Post-Operative Pain Management1R41DA043309-01 | DOORENBOS, ARDITH Z | CHANGE MANAGEMENT CONSULTING, LLC, WA | $224,949 | ZRG1 |
| 2016 | Preclinical Evaluation of NCS-382 in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)1R41NS098856-01 | GIBSON, K MICHAELMCCONNELL, ALICE | SPERAGEN, INC., TX | $224,936 | ZRG1 |
| 2016 | Polar sampling and optimization of protein-ligand cocrystal structures1R41GM116300-01A1 | BAJAJ, CHANDRAJIT LREYNOLDS, CHARLES H. | GFREE BIO, LLC, PA | $224,934 | ZRG1 |
| 2016 | Empowering real-time, web-based genomic big data analysis at commercial scale.1R41HG009096-01 | MARTH, GABOR TMILLER, CHASEWARD, ALISTAIR | FRAMESHIFT LABS, INC., MA | $224,920 | ZRG1 |
| 2016 | Targeted Epigenetic Therapy for Triple-Negative Breast Cancer1R41CA203067-01A1 | ZHOU, MING-MING | PARKSIDE SCIENTIFIC, INC., NY | $224,890 | ZRG1 |
| 2016 | A Platform Technology for High-Throughput Screening of Gene Regulatory Elements1R41GM119914-01A1 | CRAWFORD, GREGORY EGERSBACH, CHARLES A.REDDY, TIMOTHY E | ELEMENT GENOMICS, INC., NC | $224,881 | ZRG1 |
| 2016 | Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing1R41TR001270-01A1 · under PA-14-072 | CURLEY, JABE LMOORE, MICHAEL J | AXOSIM, INC., LA | $224,859 | ZRG1 |
| 2016 | Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons1R41DA041959-01 | MEHALSO, ROBERT | SENSODX II, LLC, NY | $224,840 | ZRG1 |
| 2016 | Novel Medical Food for the Management of Iron Deficiency Anemia1R41DK105656-01A1 | WOLFE, DARREN | SIDERO BIOSCIENCE, LLC, PA | $224,836 | ZRG1 |
| 2016 | Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies1R41NS097047-01 | CHAN, SHERINE S | NEUROENE THERAPEUTICS INC, DC | $224,804 | ZRG1 |
| 2016 | Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects1R41AI122574-01 · under PA-14-072 | VANDENBARK, ARTHUR A. | VIROGENOMICS BIODEVELOPMENT, INC., OR | $224,796 | ZRG1 |
| 2016 | Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss1R41AT008922-01A1 | BAO, JIANXIN | GATEWAY BIOTECHNOLOGY, INC., MO | $224,701 | ZRG1 |
| 2016 | Shape RNA Structure Analysis for Drug Discovery and Translational Research1R43GM116274-01 · under PA-14-072 | WARNER, KATHERINE DEIGAN | RIBOMETRIX, LLC, NC | $224,700 | ZRG1 |
| 2016 | Controlled Release Polymer Structures for In Situ Chemical Oxidation of Contaminated Groundwater1R41ES026916-01 | CARPENTER, ALEXIS WELLS | AXNANO, LLC, NC | $224,670 | ZRG1 |
| 2016 | Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes1R42DK108305-01 · under PA-14-072 | KLEIN, SAMUELTHAI, DUNG L | REMD BIOTHERAPEUTICS, INC., CA | $224,664 | ZRG1 |
| 2016 | SHAPE RNA Bioinformatics for Therapeutics and Translational Research1R41GM117712-01 · under PA-14-072 | WEEKS, KEVIN M | RIBOMETRIX, LLC, NC | $224,636 | ZRG1 |
| 2016 | Device for Treatment of Congenital Diaphragmatic Hernia1R41HL131250-01 · under PA-14-072 | GOLDMAN, KENNETH GLEN | H-CUBED, INC., OH | $224,634 | ZRG1 |
| 2016 | improving Cas9 mediated homologous recombination in pluripotent stem cells1R41GM115028-01A1 · under PA-14-072 | ZHANG, JIFENG | APPLIED STEMCELL, INC., CA | $224,518 | ZRG1 |
| 2016 | Engineering stem cells to make mucopolysaccharidosis IIIB1R41NS092221-01A1 · under PA-14-072 | EKINS, SEAN | PHOENIX NEST, INC., NY | $224,469 | ZRG1 |
| 2016 | Novel therapies for inherited muscle diseases1R41AR068158-01A1 · under PA-14-072 | KANG, PETER B. | MEDOSOME BIOTEC, LLC, FL | $224,463 | ZRG1 |
| 2016 | Cognitive Change Battery: An Assessment for Serial Administration1R41AG052218-01A1 | MAYR, ULRICH ERODE, CATRIN | COGMETRIC, LLC, OR | $224,370 | ZRG1 |
| 2016 | CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells1R41AI126905-01 | ALLBRITTON, NANCY L. | CELL MICROSYSTEMS, INC., NC | $224,129 | ZRG1 |
| 2016 | Cancer Imaging and Therapy Platform1R41CA213601-01 | WILSON, DAVID LYNN | BIOINVISION, INC., OH | $224,116 | ZRG1 |
| 2016 | New piperazines effecting Abeta oligomer displacement from neuronal receptors1R41AG052252-01 · under PA-14-072 | IZZO, NICHOLAS JOHN | COGNITION THERAPEUTICS, INC., PA | $224,002 | ZRG1 |
| 2016 | Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain1R41NS095436-01 · under PA-14-072 | KOPIN, ALAN S | ON TARGET THERAPEUTICS, LLC, MA | $223,900 | ZRG1 |
| 2016 | Dual-view endoscopic probe1R41CA203212-01 · under PA-14-072 | BANERJEE, BHASKARCOOMBS, DAVID | OMNISCIENT IMAGING, INC., AZ | $223,761 | ZRG1 |
| 2016 | Sample-free onsite detection of cocaine using microneedles via laser-treated skin1R41DA041003-01 · under PA-14-072 | WU, MEI XXIE, XINMIN SIMON | AFASCI, INC., CA | $223,633 | ZRG1 |
| 2016 | Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma1R41CA213488-01 | MARCOUX, FRANK W. | LEUKOGENE THERAPEUTICS, INC., SC | $222,958 | ZRG1 |
| 2016 | Delivery of pathogen-trapping antibodies for vaginal protection1R41AI122472-01 · under PA-14-072 | MOENCH, THOMAS RAY | MUCOMMUNE, LLC, NC | $222,725 | ZRG1 |
| 2016 | Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.1R41AG054337-01 | KLEIN, WILLIAM L | ACUMEN PHARMACEUTICALS, INC., VA | $222,192 | ZRG1 |
| 2016 | Advanced Polymer-Based Micro-sensor for Radiation Detection and Measurement1R41ES027389-01A1 | HOBSON, STEPHEN TERRENCE | SEACOAST SCIENCE, INC., CA | $221,432 | ZRG1 |
| 2016 | An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care1R41HD087021-01 · under PA-14-072 | KASSAM-ADAMS, NANCYMCLAUGHLIN, JEFFERY | RADIANT CREATIVE GROUP, LLC, TX | $220,945 | ZRG1 |
| 2016 | Development of a Genotype-linked Antibiotic Resistance Platform for Real Time Pathogen Risk Classification and Epidemiology1R41AI122740-01A1 | CHAN, PATRICIA | MAVERIX BIOMICS, INC., CA | $219,655 | ZRG1 |
| 2016 | Nanoliter electron paramagnetic resonance sensor based on diamond nanophotonics: a new tool for biomarker monitoring1R41GM119925-01 | ACOSTA, VICTOR MARCELJARMOLA, ANDREJS | ODMR TECHNOLOGIES, INC., CA | $216,281 | ZRG1 |
| 2016 | Nasal Leptin - Polymer Conjugate for Treatment of Obesity1R41DK108466-01A1 | KABANOV, ALEXANDER V | NEURO10-9 PHARMA, INC., NC | $215,843 | ZRG1 |
| 2016 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis1R41AR069416-01A1 | ASTRUC DIAZ, FANNY | DERMAXON, LLC, MT | $215,640 | ZRG1 |
| 2016 | A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes1R41AR068202-01A1 · under PA-14-072 | LOTZ, JEFFREY C. | BIONIKS, INC., CA | $215,600 | MRS |
| 2016 | Improved Otologic Implants On Demand Intraoperatively with 3D CAD/CAM Autografts1R41DC015408-01 | KNOX, ALISAKNOX, GLENN | NITINETICS, LLC, FL | $214,976 | ZRG1 |
| 2016 | Technology for Synthesis of Chemically Diverse RNAs1R41GM121103-01 | SOUSA, RUI J. | BIOLYTIC LAB PERFORMANCE, INC., CA | $213,601 | ZRG1 |
| 2016 | Novel Dental Adhesives to Prevent Recurrent Caries1R41DE026085-01 | RENNE, WALTER G. | CURE INNOVATIONS, LLC, SC | $211,441 | ZRG1 |
| 2016 | Developing an Affordable and Pocketable POC Device for Monitoring Lithium and Sodium in Patients with Bipolar Disorder1R41MH111337-01 | LAN, TIAN | GLUCOSENTIENT, INC., IL | $210,971 | ZRG1 |
| 2016 | "Speed Bumps": A non-invasive quantitative test for early detection of neuropathy in the feet1R41NS097120-01A1 | KENNEDY, WILLIAM R | NEURO DEVICES, INC., MN | $210,245 | ZRG1 |
Showing the 200 most recent of 559 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.